Hogan Lovells advises pSivida Corp. on its acquisition of Icon Bioscience as it rebrands as EyePoint Pharmaceuticals
Hogan Lovells advised pSivida Corp. on its acquisition of Icon Bioscience, Inc. as part of its rebranding initiative into EyePoint Pharmaceuticals, Inc. pSivida, which officially became EyePoint on 29 March 2018, is a specialty biopharmaceutical company that develops and commercializes ophthalmic products. Icon is also a specialty biopharmaceutical company whose flagship drug, DEXYCU™, is administered at the end of ocular surgery to treat postoperative inflammation.